- Recently public TetraLogic Pharmaceuticals (TLOG +4%) trades higher in early action.
- Helping the cause is Needham's Chad Messer, who has initiated the shares at Buy with a $16 price target.
- TLOG "is now developing birinapant as a best-in-class IAP inhibitor with a well established safety profile in multiple indications for cancer and infectious disease," Messer notes.
Needham starts TetraLogic Pharma at Buy
Jan 6 2014, 11:14 ET